



Express Mail No.: **ED 608 969 375 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Marchalonis *et al.*

Confirmation No.: 5233

Application No.: 09/591,789

Group Art Unit: 1648

Filed: June 12, 2000

Examiner: Jeffrey S. Parkin

For: MODULATION OF IMMUNE RESPONSE
AND METHODS BASED THEREON

Attorney Docket No.: 7760-012

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.56 AND §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references A01, B01-B11 and C04-C74 listed on the attached form entitled "List of References Cited by Applicant."

Copies of references B01-B11 and C04-C74 are submitted herewith. A copy of reference A01 is not submitted herewith because it is a U.S. patent application publication. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed reference is not meant to be construed as an admission of Applicant or Attorneys for Applicants that such reference is available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Since this Supplemental Information Disclosure Statement is being filed in the United States Patent and Trademark Office concurrently with a Request for Continued Examination under 37 C.F.R. § 1.114, pursuant to 37 C.F.R. § 1.97(b)(4), Applicants believe that no fee is due. However, should the Patent and Trademark Office determine otherwise, please charge any required fee to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted, *by: Sebastian Kuthnick*
Reg. No. 52,413

Date: April 9, 2007

Thomas E. Friebe 29,258
Thomas E. Friebe (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**
(Use several sheets if necessary)

ATTY. DOCKET NO.

7760-012

APPLICATION NO.

09/591,789

APPLICANT

Marchalonis *et al.*

FILING DATE

June 12, 2000

ART UNIT

1648

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	2004/0248192	12/09/04	Marchalonis et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	EP 0 109 942	05/30/84	Morein		
	B02	EP 0 180 564	05/07/86	Morein		
	B03	EP 0 231 039	08/05/87	De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn		
	B04	GB 2 189 141	10/21/87	Ribi Immunochem Research Inc.		
	B05	WO 91/10736	07/25/91	Dana Farber Cancer Institute		
	B06	WO 92/01715	02/06/92	The Board of Trustees of the Leland Stanford Junior University		
	B07	WO 94/18317	08/18/94	The Board of Trustees of the Leland Stanford Junior University		
	B08	WO 95/18145	07/06/95	The Austin Research		
	B09	WO 96/21028	07/11/96	Procept, Inc.		
	B10	WO 97/35991	10/02/97	The Johns Hopkins University		
	B11	WO 02/094860	11/28/02	The Arizona Board of Regents on behalf of the University of Arizona		

EXAMINER**DATE CONSIDERED***EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO.

7760-012

APPLICATION NO.

09/591,789

APPLICANT

Marchalonis *et al.*

FILING DATE

June 12, 2000

ART UNIT

1648

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C04	AKUFFO <i>et al.</i> , 1999, "Natural killer cells in cross-regulation of IL-12 by IL-10 in Leishmania antigen-stimulated blood donor cells," <i>Clin. Exp. Immunol.</i> 117(3):529-34	
	C05	ALBRIGHT <i>et al.</i> , 2000, "Soluble receptors and other substances that regulate proinflammatory cytokines in young and aging humans," <i>J. Gerontol. A Biol. Sci. Med. Sci.</i> 55(1):B20-5	
	C06	ALEMAN <i>et al.</i> , 2000, "Interleukin-12 amplifies the M. leprae hsp65-cytotoxic response in the presence of tumour necrosis factor-alpha and interferon-gamma generating CD56+ effector cells: interleukin-4 downregulates this effect," <i>Scand. J. Immunol.</i> 51(3):262-70	
	C07	BOON, 1993, "Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy," <i>Int. J. Cancer</i> 54(2):177-80	
	C08	BOURDETTE <i>et al.</i> , 1994, "Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides," <i>J. Immunol.</i> 152(5):2510-9	
	C09	BRADLEY <i>et al.</i> , 1994, "Alteration of in vivo cytokine gene expression in mice infected with a molecular clone of the defective MAIDS virus," <i>J. Acquir. Immune Defic. Syndr.</i> 7(1):1-9	
	C10	CASTLE <i>et al.</i> , 1997, "Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents," <i>Mech. Ageing Dev.</i> 94(1-3):7-16	
	C11	CHERWINSKI <i>et al.</i> , 1987, "Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies," <i>J. Exp. Med.</i> 166(5):1229-44	
	C12	CLERICI <i>et al.</i> , 1993, "A TH1->TH2 switch is a critical step in the etiology of HIV infection," <i>Immunol. Today</i> 14(3):107-11	
	C13	DE CARLI <i>et al.</i> , 1994, "Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity," <i>Autoimmunity</i> 18(4):301-8	
	C14	DEHGHANPISHEH <i>et al.</i> , 1995, "Production of IgG autoantibodies to TCRs in mice infected with the retrovirus LP-BMS," <i>Int. Immunol.</i> 7(1):31-6	
	C15	DEHGHANPISHEH <i>et al.</i> , 1997, "Retrovirally induced mouse anti-TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens," <i>Scand. J. Immunol.</i> 45(6):645-54	
	C16	FAUCI <i>et al.</i> , 1993, "Multifactorial nature of human immunodeficiency virus disease: implications for therapy," <i>Science</i> 262(5136):1011-8	
	C17	FERNANDEZ-GUTIERREZ <i>et al.</i> , 1999, "Early lymphocyte activation in elderly humans: impaired T and T-dependent B cell responses," <i>Exp. Gerontol.</i> 34(2):217-29	
	C18	GARCIA <i>et al.</i> , 1999, "IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection," <i>J. Immunol.</i> 162(10):6114-21	
	C19	GAZZINELLI <i>et al.</i> , "CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice," <i>J. Immunol.</i> 148(1):182-8	
	C20	GRAZIOSI <i>et al.</i> , 1996, "Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 93(9):4386-91	
	C21	HAYNES <i>et al.</i> , 1996, "Toward an understanding of the correlates of protective immunity to HIV infection," <i>Science</i> . 1996 Jan 19;271(5247):324-8	
	C22	HIRSCH <i>et al.</i> , 1999, "Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy," <i>J. Infect. Dis.</i> 180(6):2069-73	
	C23	IMBERTI <i>et al.</i> , 1991, "Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3979440v1

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

7760-012

APPLICATION NO.

09/591,789

APPLICANT

Marchalonis et al.

FILING DATE

June 12, 2000

ART UNIT

1648

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
		sequences," Science 254(5033):860-2	
	C24	INFANTE-DUARTE et al., 1999, "Th1/Th2 balance in infection," Springer Semin. Immunopathol. 21(3):317-38	
	C25	ISHIKAWA et al., 1998, "Polyclonality and multispecificity of the CTL response to a single viral epitope," J. Immunol. 161(11):5842-50	
	C26	JOLLY et al., 1999, "Calorie restriction modulates Th-1 and Th-2 cytokine-induced immunoglobulin secretion in young and old C57BL/6 cultured submandibular glands," Aging (Milano) 11(6):383-9	
	C27	KANAGAWA et al., 1993, "Resistance of mice deficient in IL-4 to retrovirus-induced immunodeficiency syndrome (MAIDS)," Science 262(5131):240-2	
	C28	KARANFILOV et al., 1999, "Age-related defects in Th1 and Th2 cytokine production by human T cells can be dissociated from altered frequencies of CD45RA+ and CD45RO+ T cell subsets," Mech. Ageing Dev. 109(2):97-112	
	C29	KAWAKAMI et al., 1997, "Human tumor antigens recognized by T-cells," Immunol. Res. 16(4):313-39	
	C30	KENNEY et al., 1999, "Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis," J. Immunol. 163(8):4481-8	
	C31	KIMURA et al., 2000, "IL-4 production by PBMCs on stimulation with mite allergen is correlated with the level of serum IgE antibody against mite in children with bronchial asthma," J. Allergy. Clin. Immunol. 105:327-32	
	C32	KLEIN et al., 1997, "Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry," AIDS 11(9):1111-8	
	C33	LEIGH et al., 1998, "Th1/Th2 cytokine expression in saliva of HIV-positive and HIV-negative individuals: a pilot study in HIV-positive individuals with oropharyngeal candidiasis," J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 19(4):373-80	
	C34	LIANG et al., 1996, "Murine AIDS, a key to understanding retrovirus-induced immunodeficiency," Viral Immunol. 9(4):225-39	
	C35	LIANG et al., 1997, "Prevention of immune dysfunction, vitamin E deficiency and loss of cryptosporidium resistance during murine retrovirus infection by T cell receptor peptide immunization," Nutr. Res. 17(4):677-692	
	C36	LIANG et al., 1997, "Prevention of retrovirus-induced aberrant cytokine secretion, excessive lipid peroxidation, and tissue vitamin E deficiency by T cell receptor peptide treatments in C57BL/6 mice," Proc. Soc. Exp. Biol. Med. 214(1):87-94	
	C37	LOHOFF et al., 1998, "Experimental murine leishmaniasis and the Th1/Th2 cell concept," Tokai J. Exp. Clin. Med. 23(6):347-50	
	C38	LONGENECKER et al., 1993, "Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant," Ann. N. Y. Acad. Sci. 690:276-91	
	C39	MARCHALONIS et al., 1999, "Recognition of defined epitopes by affinity-purified anti-immunoglobulin fab autoantibodies isolated from HIV-infected humans," J. Mol. Recognit. 12(3):169-76	
	C40	MARCHALONIS et al., 1992, "Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain," Proc. Natl. Acad. Sci. U. S. A. 89(8):3325-9	
	C41	MARCHALONIS et al., 1993, "Natural human antibodies to synthetic peptide autoantigens: correlations with age and autoimmune disease," Gerontology 39(2):65-79. Abstract only	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3979440v1

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

7760-012

APPLICATION NO.

09/591,789

APPLICANT

Marchalonis *et al.*

FILING DATE

June 12, 2000

ART UNIT

1648

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
C42	MARCHALONIS <i>et al.</i> , 1994, "Autoantibodies to T-cell receptors following infection by murine Retrovirus," <i>Lymphology</i> 27S:853-856		
C43	MARCHALONIS <i>et al.</i> , 1995, "Autoantibodies against peptide-defined epitopes of T-cell receptors in retrovirally infected humans and mice," <i>Adv. Exp. Med. Biol.</i> 383:211-22. Abstract only		
C44	MARCHALONIS <i>et al.</i> , 1997, "Binding of human IgG myeloma proteins to autologous T-cell receptor determinants," <i>Crit. Rev. Immunol.</i> 17(5-6):497-506		
C45	MARCHALONIS <i>et al.</i> , 1997, "Use of synthetic T-cell receptor derived peptides in therapy for autoimmunity and retroviral infections," <i>The Chemist</i> 74:3-9		
C46	MARCHALONIS <i>et al.</i> , 2000, "Epitope promiscuity of human monoclonal autoantibodies to T-cell receptor-combining site determinants," <i>Appl. Biochem. Biotechnol.</i> 83(1-3):31-49		
C47	MERONI <i>et al.</i> , 1996, "Evidence for type 2 cytokine production and lymphocyte activation in the early phases of HIV-1 infection," <i>AIDS</i> 10(1):23-30		
C48	MEZIERE <i>et al.</i> , 1997, "In vivo T helper cell response to retro-inverso peptidomimetics," <i>J. Immunol.</i> 159(7):3230-7		
C49	MITRA <i>et al.</i> , 1999, "Differential representations of memory T cell subsets are characteristic of polarized immunity in leprosy and atopic diseases," <i>Int. Immunol.</i> 11(11):1801-10		
C50	MORAES <i>et al.</i> , 1999, "Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL)," <i>Scand. J. Immunol.</i> 50(5):541-9		
C51	MORELAND <i>et al.</i> , 1996, "V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study," <i>J. Rheumatol.</i> 23(8):1353-62		
C52	MORELAND <i>et al.</i> , 1998, "T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides," <i>Arthritis. Rheum.</i> 41(11):1919-29		
C53	MOSMANN <i>et al.</i> , 1986, "Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins," <i>J. Immunol.</i> 136(7):2348-57		
C54	MOSMANN <i>et al.</i> , 1991, "The role of IL-10 in crossregulation of TH1 and TH2 responses," <i>Immunol. Today</i> 12(3):A49-53		
C55	MOUDGIL <i>et al.</i> , 1998, "Heterogeneity of the T cell response to immunodominant determinants within hen eggwhite lysozyme of individual syngeneic hybrid F1 mice: implications for autoimmunity and infection," <i>J. Immunol.</i> 161(11):6046-53		
C56	MOVERARE <i>et al.</i> , 2000, "Study of the Th1/Th2 balance, including IL-10 production, in cultures of peripheral blood mononuclear cells from birch-pollen-allergic patients," <i>Allergy</i> 55(2):171-5		
C57	ROBEY <i>et al.</i> , 2000, "Production and characterization of monoclonal IgM autoantibodies specific for the T-cell receptor," <i>J. Protein Chem.</i> 19(1):9-21. Abstract only		
C58	ROCHA <i>et al.</i> , 1999, "Down-regulation of Th1 type of response in early human American cutaneous leishmaniasis," <i>J. Infect. Dis.</i> 180(5):1731-4		
C59	ROMAGNANI, 1995, "Biology of human TH1 and TH2 cells," <i>J. Clin. Immunol.</i> 15(3):121-9		
C60	SELVEY <i>et al.</i> , 1993, "Preferential expansion and activation of V beta 5+ CD4+ T cells in murine acquired immunodeficiency syndrome," <i>J. Immunol.</i> 151(3):1712-22		
C61	SHER <i>et al.</i> , 1992, "Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection," <i>Immunol. Rev.</i> 127:183-204		

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

7760-012

APPLICATION NO.

09/591,789

APPLICANT

Marchalonis *et al.*

FILING DATE

June 12, 2000

ART UNIT

1648

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C62	SOLANA <i>et al.</i> , 2000, "NK and NK/T cells in human senescence," <i>Vaccine</i> 18(16):1613-20	
	C63	SOUDEYNS <i>et al.</i> , 1993, "The T cell receptor V beta repertoire in HIV-1 infection and disease," <i>Semin. Immunol.</i> 5(3):175-85	
	C64	TIMM <i>et al.</i> , 1999, "Maturation of CD4+ lymphocytes in the aged microenvironment results in a memory-enriched population," <i>J. Immunol.</i> 162(2):711-7	
	C65	VALENTIN <i>et al.</i> , 1998, "Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression," <i>Proc. Natl. Acad. Sci. U. S. A.</i> 95(15):8886-91	
	C66	VANDENBARK <i>et al.</i> , 1996, "Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial," <i>Nat. Med.</i> 2(10):1109-15	
	C67	VICTOR-KOBRIN <i>et al.</i> , 1989, "Structural correlates of a regulatory idiotope," <i>Immunol. Rev.</i> 110:151-71	
	C68	VIGANO <i>et al.</i> , 1995, "Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression," <i>J. Pediatr.</i> 126(3):368-74	
	C69	WANG <i>et al.</i> , 1993, "The kinetics of imbalanced cytokine production by T cells and macrophages during the murine AIDS," <i>Adv. Biosci.</i> 86:335-340	
	C70	WANG <i>et al.</i> , 1994, "Anti-IL-4 monoclonal antibody and IFN-gamma administration retards development of immune dysfunction and cytokine dysregulation during murine AIDS," <i>Immunology</i> 83(3):384-9	
	C71	WATSON <i>et al.</i> , 1989, "Minireview: Murine models for acquired immune deficiency syndrome," <i>Life Sciences</i> 44:iii-xv	
	C72	WILSON <i>et al.</i> , 1997, "Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations," <i>J. Neuroimmunol.</i> 76(1-2):15-28	
	C73	YANAGI <i>et al.</i> , 1984, "A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains," <i>Nature</i> 308(5955):145-9	
	C74	YSSEL <i>et al.</i> , 2000, "Characterization of T cell subpopulations involved in the pathogenesis of asthma and allergic diseases," <i>Int. Arch. Allergy Immunol.</i> 121(1):10-8	

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYI-3979440v1